lung cancer Archives | Page 2 of 3

Oncotarget News

Figure 7: Effects of TGF-β receptor inhibitor EW7197 with and without TGF-β1 for LSR, TRIC, OCLN, and CLDN-2 in human lung epithelial cells (HLE) cells with and without 10% FBS.

Downregulation of Angulin-1/LSR Induces Malignancy in Lung Adenocarcinoma

March 29, 2023

In the present study, we found that downregulation of angulin-1/LSR induced malignancy via upregulation of EGF-dependent CLDN-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma.” BUFFALO, NY-... read more

Figure 5: NSL-YHJ-2-27 suppresses cancer cell migration and invasion.

Oncotarget

Oncotarget | Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cells

March 28, 2023

mutations in G-proteins have been associated in the progress of several cancers [...]” BUFFALO, NY- March 28, 2023 – A new research paper was published in Oncotarget's Volume 14 on March... read more

Oncotarget

Oncotarget | Tumor Hyaluronan as Novel Biomarker in Non-Small Cell Lung Cancer: A Retrospective Study

November 9, 2022

To the best of our knowledge, there have only been 2 other studies (both retrospective) investigating the prognostic potential of HA in NSCLC patients [5, 6].”BUFFALO, NY- November 9,... read more

Oncotarget

Oncotarget | Therapeutic Efficacy of Humanized JAA-F11 Anti-Thomsen-Friedenreich Antibody Constructs H2aL2a and H3L3 in Human Breast and Lung Cancer Xenograft Models

October 25, 2022

The potential therapeutic efficacy of the humanized antibodies to TF-Ag-α, hJAA-F11-H2aL2a and hJAA-F11-H3L3, was assessed in human breast and lung cancer xenograft models.”BUFFALO, NY- October 25, 2022 – A new... read more

Oncotarget

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

July 11, 2022

Dr. Robert Hsu from the University of Southern California, Norris Comprehensive Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of... read more

Oncotarget

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

June 14, 2022

Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in... read more

Figure 2: TMB distribution in non-small cell lung cancer

Oncotarget

Mutational Burden in Lung Cancer Studied in Multisite Cohort

April 25, 2022

BUFFALO, NY-April 25, 2022 – A new research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget... read more

Oncotarget

Behind the Study: Targeting Stem Cells in Non-Small Cell Lung Cancer

March 25, 2022

Dr. Beatrice Aramini and Dr. Valentina Masciale from the University of Modena and Reggio Emilia details a 2020 research paper she co-authored and published by Oncotarget, entitled, “CD44+/EPCAM+... read more

Dr. Aditya Kulkarni from The Lantern Pharma, Inc.

Oncotarget

Behind the Study: Retaining Nanomolar Potency in Lung Cancer

August 16, 2021

Behind the Study is a series of transcribed videos from researchers elaborating on their recent oncology-focused studies published by Oncotarget. A new Behind the Study is released each... read more

Frank Slack, professor in the department of pathology at Beth Israel Deaconess Medical Center at Harvard Medical School

Oncotarget

Behind the Study: miRNA-185 Emerges as Regulator of KRAS

April 19, 2021

Behind the Study is a series of transcribed videos from researchers elaborating on their recent oncology-focused studies published in Oncotarget. A new Behind the Study is released each Monday. Visit... read more